Insider Trading History of Somaiya Mayur Ian

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Somaiya Mayur Ian since 2020. This trader's CIK number is 1760303. At the time of last reporting, Somaiya Mayur Ian was the Chief Financial Officer of Newamsterdam Pharma Co N.v.. (stock ticker symbol NAMS). Also see all insider trading activities at Newamsterdam Pharma Co N.v..

Note that in the past Somaiya Mayur Ian also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Newamsterdam Pharma Co N.v. (NAMS) by Somaiya Mayur Ian

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2026 NAMS 0 $0 5,118 $170,173 0 $0

Yearly summary of insider trading at Tcr2 Therapeutics Inc. (TCRR) by Somaiya Mayur Ian

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2020 TCRR 0 $0 5,666 $179,980 4,000 $23,520


Insider trading activities at 2 companies by Somaiya Mayur Ian:

1. Newamsterdam Pharma Co N.v. (NAMS)

2. Tcr2 Therapeutics Inc. (TCRR)

Table 1. Insider trading of Newamsterdam Pharma Co N.v. (NAMS) by Somaiya Mayur Ian

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2026-01-05 NAMS Sale 5,118 33.25 170,173

Table 2. Insider trading of Tcr2 Therapeutics Inc. (TCRR) by Somaiya Mayur Ian

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2020-12-14 TCRR Sale 2,000 35.00 70,000
2020-12-14 TCRR Option Ex 2,000 5.88 11,760
2020-11-17 TCRR Sale 3,666 30.00 109,980
2020-11-17 TCRR Option Ex 2,000 5.88 11,760

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Somaiya Mayur Ian (Chief Financial Officer of Newamsterdam Pharma Co N.v. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.